Date: 2015-11-02
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 6th World Congress on Targeting Mitochondria in Berlin
Company: Neurovive Pharmaceutical (Sweden)
Product: NVP015 - Complex I Deficiency discovery program including succinate prodrug candidates
Action mechanism:
Disease: mitochondrial disorders associated with complex I deficiency such as Leigh Syndrome
Therapeutic area: Rare diseases - Neurodegenerative diseases
Country:
Trial details:
Latest
news: * On November 2, 2015, NeuroVive Pharmaceutical announced the presentation of preclinical data from its Complex I Deficiency discovery program at the 6th World Congress on Targeting Mitochondria in Berlin, Germany. NeuroVive’s Complex I Deficiency discovery program, also known as NVP015, is focused on the generation of novel drug candidates that target mitochondrial energy regulation in a number of mitochondrial disorders associated with complex I deficiency such as Leigh Syndrome.
The research presented focuses on the role of NeuroVive’s succinate prodrug candidates in mitochondrial respiration, a key component of mitochondrial energy production. Using a model of healthy cells and cells from a Leigh Syndrome patient, the research team demonstrated that succinate prodrug candidates increased mitochondrial respiration. The research was developed by NeuroVive’s scientific team, including young PhD researcher Sarah Piel who presented the findings to leaders in the field of mitochondrial medicine.
The next steps in the Complex I Deficiency discovery program involves the synthesis and scaled up manufacture of the most promising candidates, pharmacokinetic studies and early formulation and in vivo proof of concept work. It is anticipated that NeuroVive will select a final drug candidate for further development in 2016.
